Ortin Global Ltd
Tue 29/04/2025,15:40:8 | NSE : ORTINGLOBE
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 11.15
Previous Close
₹ 11.08
Volume
38129
Mkt Cap ( Rs. Cr)
₹8.55
High
₹ 11.54
Low
₹ 10.52
52 Week High
₹ 24.82
52 Week Low
₹ 9.64
Book Value Per Share
₹ 3.47
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Ortin Global Ltd
Your Vote -
Buy
92.68%
Hold
4.88%
Sell
2.44%
92.68%
41 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Ortin Global Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Ortin Global L - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
-
Ortin Global L has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Ortin Global L - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Ortin Global L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Ortin Global L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Ortin Global L - Outcome of Board Meeting
-
Ortin Global L - Board Meeting Outcome for Outcome Of Board Meeting
-
Ortin Global L - Outcome of Board Meeting
-
Ortin Global L - Trading Window-XBRL
-
Ortin Global L - Trading Window
-
Ortin Global L - Copy of Newspaper Publication
-
Ortin Global L - Integrated Filing- Financial
-
Ortin Global L - Integrated Filing (Financial)
-
Ortin Global L - UN-AUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31-12-2024
-
Ortin Global L - Financial Result Updates
-
Ortin Global L - Outcome of Board Meeting
-
Ortin Global L - Board Meeting Outcome for OUTCOME OF BOARD MEETING FOR APPROVAL OF UN-AUDITED FINANCIALS OF THE COMPANY FOR
-
Ortin Global L - Board Meeting Intimation
-
Ortin Global L - Board Meeting Intimation for Approval Of Un-Audited Financials Of The Company For The Quarter Ended 31-12-20
Key fundamentals
Evaluate the intrinsic value of Ortin Global Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 4.6262 | 17.3116 | 17.1011 | 18.2972 | 43.3875 |
Liabilities | 4.6262 | 17.3116 | 17.1011 | 18.2972 | 43.3875 |
Equity | 8.1314 | 8.1314 | 8.1313 | 8.1313 | 16.9404 |
Gross Profit | -6.5371 | 0.5207 | 0.3799 | 1.2452 | 5.7083 |
Net Profit | -8.041 | -0.0936 | -0.3987 | 0.9454 | -0.5639 |
Cash From Operating Activities | -4.7871 | -0.2533 | 2.1523 | 18.0343 | 6.2269 |
NPM(%) | -380.81 | -1.55 | -4.84 | 11.57 | -0.28 |
Revenue | 2.1115 | 6.0203 | 8.2307 | 8.1674 | 197.391 |
Expenses | 8.6486 | 5.4996 | 7.8508 | 6.9221 | 191.6827 |
ROE(%) | -284.74 | -3.31 | -14.11 | 33.48 | -19.96 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Ortin Global Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 840.85 | 0.23 | 11.87 | 6.11 | 1321.50 | 1.37 |
Lotus Eye Hospital and Institute Ltd | 81.36 | 2.94 | 339.00 | 22.27 | 14.01 | 0.61 |
Vaishali Pharma Ltd | 13.72 | -0.15 | 457.33 | 11.48 | 2.76 | 0.00 |
Astec Lifesciences Ltd | 693.05 | -1.61 | 0.00 | 21.00 | -687.11 | 0.00 |
Company Info
ORTIN LABORATORIES LIMITED, a Trusted Reliance for Quality established in the year 1986 as a Private Limited Company with a nominal capital of One lakh rupees to offer QUALITY Drugs and Medicines to the suffering mankind. Later, in the year 1994, this Private Limited Company converted as a Public Limited Company with 5,060 shareholders which received good subscription from the Public. These proceeds were utilised for constructing a Factory in a spacious area of 25000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of TABLETS, CAPSULES, SYRUPS, DRY POWDERS & OINTMENTS. Due to our concern for QUALITY, we stand as a leading and predominant Pharmaceutical Manufacturer of Drugs and Medicines of our country with turnover running in crores of rupees. Ortin has been certified as an ISO 9001: 2000 Company by the internationally recognised Quality Management Certification Body, the National Quality Assurance, UK in pursuance of its focus towards Quality with its Policy to enhance customer satisfaction by providing Quality Pharmaceutical Formulations at optimum cost and maintain profitability through continual improvement of Quality Management Sytems and cGMP. Ortin, a Public Limited Company, presently trading in the Hyderabad & Madras Stock Exchanges shall shortly commence their trading with the Bombay Stock Exchange. Ortin is honored as a registered Supplier of Drugs & Medicines with the most reputed Central, State & Quasi-Government Organizations & Institutions of our Country such as the Railways, Health Ministry, Defence, Posts & Telegraph, Electricity Hospitals, Transport Organizations, Research Institutions such as JIPMER, IICT etc. Quality is the Hallmark of Ortin. At every stage of Production from Raw Material to Finished Products, highest standard of Quality is ensured with the help of most modern equipment and experienced personnel. This unflinching perseverance towards quality has helped the company to earn enormous goodwill & trust, both from medical profession and pharmaceutical trade. Being in partnership with the world means respecting its resources without compromise and so at Ortin, continuous process evaluation and monitoring waste recoveries ensure that the focus is maintained. Specialized facilities have helped us to earn a reputation for the expert handling of hazardous materials in the form of reactants and products. Teams from the Ministry of Health regularly inspect our Plant. Every care is taken for treatment of solid wasters, discharged liquids and atmospheric releases. Ortin is contemplating an entry into the OTC Segment as part of its long term growth strategy. It is channeling its efforts towards building an overseas marketing network in order to enhance exports to third world countries. Ortin proposes to be certified as a WHO GMP Unit and to launch innovative Biotechnology products in Orthopedic and Dental Segments. The success behind us is only the Reliance which we carry for our Quality from the people all over the country. Our motto, right from our inception has been towards Quality and we still maintain them and continue to do so in future. Recognitions -Ortin's formulation unit has been certified as a WHO GMP CERTIFIED manufacturing unit and as an ISO 9001: 2008 Company by the internationally recognised Quality Management Certification Body, the BMQR & Accredited by AIAO-BAR, USA in pursuance of its focus towards Quality with its Policy to enhance customer satisfaction by providing Quality Pharmaceutical Formulations at optimum cost and maintain profitability through continual improvement of Quality Management Systems and cGMP. -Its Drug API Intermediates manufacturing unit has been certified as an ISO 9001: 2008 company by BMQR & Accredited by AIAO-BAR, USA for its quality systems management which shows the quality conscious to deliver best quality products. 2007 -Ortin Laboratories signs 2-year marketing agreement with Canadian Firm 2008 -Ortin Laboratories Recommendation of dividend of 8% 2009 -Ortin Laboratories has recommended 8% dividend 2011 -Ortin Laboratories has recommended Dividend of Rs. 0.50 per equity share. 2012 -Ortin Laboratories has recommended 5% 2013 - Ortin Laboratories Ltd has a Dividend of Rs. 0.25 per share. 2015 -Ortin Laboratories Ltd is listed on BSE. -Ortin Laboratories changed the Register office within the city limits. 2017 - Company board approved demerger of Undertaking related to API Intermediates Division (Unit - II) of M/s Ortin Laboratories Limited into M/s Vineet Laboratories Limited by way of demerger procedure under sections 230-232 of the Companies Act, 2013 and other relevant provisions of the Companies Act, 2013, 2024 -The Company name has changed to Ortin Global Ltd. from Ortin Laboratories Ltd.
ORTIN LABORATORIES LIMITED, a Trusted Reliance for Quality established in the year 1986 as a Private Limited Company with a nominal capital of One lakh rupees to offer QUALITY Drugs and Medicines to the suffering mankind. Later, in the year 1994, this Private Limited Company converted as a Public Limited Company with 5,060 shareholders which received good subscription from the Public. These proceeds were utilised for constructing a Factory in a spacious area of 25000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of TABLETS, CAPSULES, SYRUPS, DRY POWDERS & OINTMENTS. Due to our concern for QUALITY, we stand as a leading and predominant Pharmaceutical Manufacturer of Drugs and Medicines of our country with turnover running in crores of rupees. Ortin has been certified as an ISO 9001: 2000 Company by the internationally recognised Quality Management Certification Body, the National Quality Assurance, UK in pursuance of its focus towards Quality with its Policy to enhance customer satisfaction by providing Quality Pharmaceutical Formulations at optimum cost and maintain profitability through continual improvement of Quality Management Sytems and cGMP. Ortin, a Public Limited Company, presently trading in the Hyderabad & Madras Stock Exchanges shall shortly commence their trading with the Bombay Stock Exchange. Ortin is honored as a registered Supplier of Drugs & Medicines with the most reputed Central, State & Quasi-Government Organizations & Institutions of our Country such as the Railways, Health Ministry, Defence, Posts & Telegraph, Electricity Hospitals, Transport Organizations, Research Institutions such as JIPMER, IICT etc. Quality is the Hallmark of Ortin. At every stage of Production from Raw Material to Finished Products, highest standard of Quality is ensured with the help of most modern equipment and experienced personnel. This unflinching perseverance towards quality has helped the company to earn enormous goodwill & trust, both from medical profession and pharmaceutical trade. Being in partnership with the world means respecting its resources without compromise and so at Ortin, continuous process evaluation and monitoring waste recoveries ensure that the focus is maintained. Specialized facilities have helped us to earn a reputation for the expert handling of hazardous materials in the form of reactants and products. Teams from the Ministry of Health regularly inspect our Plant. Every care is taken for treatment of solid wasters, discharged liquids and atmospheric releases. Ortin is contemplating an entry into the OTC Segment as part of its long term growth strategy. It is channeling its efforts towards building an overseas marketing network in order to enhance exports to third world countries. Ortin proposes to be certified as a WHO GMP Unit and to launch innovative Biotechnology products in Orthopedic and Dental Segments. The success behind us is only the Reliance which we carry for our Quality from the people all over the country. Our motto, right from our inception has been towards Quality and we still maintain them and continue to do so in future. Recognitions -Ortin's formulation unit has been certified as a WHO GMP CERTIFIED manufacturing unit and as an ISO 9001: 2008 Company by the internationally recognised Quality Management Certification Body, the BMQR & Accredited by AIAO-BAR, USA in pursuance of its focus towards Quality with its Policy to enhance customer satisfaction by providing Quality Pharmaceutical Formulations at optimum cost and maintain profitability through continual improvement of Quality Management Systems and cGMP. -Its Drug API Intermediates manufacturing unit has been certified as an ISO 9001: 2008 company by BMQR & Accredited by AIAO-BAR, USA for its quality systems management which shows the quality conscious to deliver best quality products. 2007 -Ortin Laboratories signs 2-year marketing agreement with Canadian Firm 2008 -Ortin Laboratories Recommendation of dividend of 8% 2009 -Ortin Laboratories has recommended 8% dividend 2011 -Ortin Laboratories has recommended Dividend of Rs. 0.50 per equity share. 2012 -Ortin Laboratories has recommended 5% 2013 - Ortin Laboratories Ltd has a Dividend of Rs. 0.25 per share. 2015 -Ortin Laboratories Ltd is listed on BSE. -Ortin Laboratories changed the Register office within the city limits. 2017 - Company board approved demerger of Undertaking related to API Intermediates Division (Unit - II) of M/s Ortin Laboratories Limited into M/s Vineet Laboratories Limited by way of demerger procedure under sections 230-232 of the Companies Act, 2013 and other relevant provisions of the Companies Act, 2013, 2024 -The Company name has changed to Ortin Global Ltd. from Ortin Laboratories Ltd.
Read More
Parent Organisation
Ortin Global Ltd.
Founded
27/10/1986
Managing Director
Mr.S Murali Krishna Murthy
NSE Symbol
ORTINGLOBEBE
FAQ
The current price of Ortin Global Ltd is ₹ 10.52.
The 52-week high for Ortin Global Ltd is ₹ 11.54 and the 52-week low is ₹ 10.52.
The market capitalization of Ortin Global Ltd is currently ₹ 8.55. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Ortin Global Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Ortin Global Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Ortin Global Ltd shares.
The CEO of Ortin Global Ltd is Mr.S Murali Krishna Murthy, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.